Clinical Trial Update: Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 dose-finding trial of Empegfilgrastim for preventing chemotherapy-induced neutropenia in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Neutropenia

Drugs mentioned

• Empegfilgrastim (empegfilgrastim)

Snippet

Sponsor: Biocad | Conditions: Chemotherapy-induced Neutropenia | Phase 2 | Status: COMPLETED | Results posted: 2016-10-24